Psychoonkologische Aspekte in der CML-Behandlung
- 18 May 2020
- journal article
- Published by Springer Science and Business Media LLC in InFo Hämatologie + Onkologie
- Vol. 23 (5), 14-17
- https://doi.org/10.1007/s15004-020-8108-2
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemiaAnnals of Hematology, 2020
- Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapyMedicine, 2019
- Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemiaZeitschrift für Krebsforschung und Klinische Onkologie, 2019
- Chronic Myeloid Leukemia Patient’s Voice About the Experience of Treatment-Free Remission Failure: Results From the Italian Sub-Study of ENESTPath Exploring the Emotional Experience of Patients During Different Phases of a Clinical TrialFrontiers in Psychology, 2019
- A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitorsCancer Medicine, 2018
- Health-Related Quality of Life in Patients With Chronic Myeloid Leukemia Receiving First-Line Therapy With NilotinibCancer, 2018
- Long-Term Patient-Reported Outcomes From an Open-Label Safety and Efficacy Study of Bosutinib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients Resistant or Intolerant to Prior TherapyCancer, 2018
- Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinibLeukemia, 2013
- Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparisonSupportive Care in Cancer, 2012
- Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?Annals of Hematology, 2012